Stock XERS XERIS BIOPHARMA HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Xeris Biopharma Holdings, Inc.

Equities

XERS

US98422E1038

Real-time Estimate Cboe BZX
Other stock markets
 18:40:59 29/04/2024 BST 		5-day change 1st Jan Change
1.755 USD +0.29% Intraday chart for Xeris Biopharma Holdings, Inc. -2.24% -25.95%
03-28 Oppenheimer Initiates Coverage on Xeris Biopharma With Outperform Rating, $5 Price Target MT
03-18 Xeris Biopharma Holdings, Inc.(NasdaqGS:XERS) added to S&P Pharmaceuticals Select Industry Index CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Xeris Biopharma Holdings, Inc. Provides Earnings Guidance for the Year 2024
Xeris Biopharma Holdings Seeks Acquisitions
US Equity Markets Close Higher Wednesday as Investors Await Inflation Data
Sector Update: Health Care Stocks Gain Late Afternoon
Xeris Biopharma Shares Rise on Licensing Agreement With Amgen
Xeris Biopharma Enters into an Exclusive Worldwide License Agreement for Xeriject Formulation of Teprotumumab
Sector Update: Health Care Stocks Stronger Late Afternoon
Sector Update: Health Care Stocks Gain Thursday Afternoon
Sector Update: Health Care
Xeris Biopharma Expects 2023 Revenue to be at High End of Previous Guidance; Shares Jump
Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Year 2024
Xeris Biopharma Holdings, Inc. Revises Revenue Guidance for the Year 2023
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Xeris Biopharma Holdings, Inc. Revises Revenue Guidance for the Full Year 2023
Investors Await Fed Decision as US Futures Move Lower in Wednesday's Premarket Activity
Top Premarket Gainers
Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2023
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Xeris Biopharma Reports First Participant Dosed in Mid-Stage Hypothyroidism Trial
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XERS Stock
  4. News Xeris Biopharma Holdings, Inc.
  5. Other languages